Our leadership team has studied hepatitis in great research institutes, dirt-floored clinics and, in one case, in his own body.
The Oversight Committee governs and manages EndHep2030, which is fiscally sponsored by RPA.
Charles Gore Medicines Patent Pool
Mr. Charles Gore (Geneva, Switzerland) is executive director of the Medicines Patent Pool. He took up the post in July 2018 following a career in patient representation and public health advocacy.
Charles was diagnosed with hepatitis C in 1995 and cirrhosis in 1998; in 2002, he was treated and cured of the virus. In 2000 Charles set up The Hepatitis C Trust in the UK which he ran for 18 years. He helped create the European Liver Patients Association and was its first President in 2004. In 2007 Charles organized a meeting of hepatitis patient organizations from around the world to agree on coordinated global action. From this emerged the decision to hold an annual World Hepatitis Day and to create a new non-governmental organization, the World Hepatitis Alliance, of which Charles was the President from 2007 until the end of 2017. As a result of advocacy by the Alliance and its members, the World Health Organization (WHO) adopted successive viral hepatitis resolutions in 2010, 2014 and 2016, making World Hepatitis Day an official day, celebrated on 28 July every year, and endorsing the first Global Health Sector Strategy on viral hepatitis with the goal of eliminating hepatitis B and C by 2030.
In addition to direct advocacy with over 50 Ministries of Health, Charles has advised countries on finding sustainable domestic financing for hepatitis programs, including health system elements such as infection control and, blood and injection safety. Charles also sits on a number of national and international advisory bodies, including the WHO Director-General’s Strategic and Technical Advisory Committee for Viral Hepatitis and has been a member of all of the WHO guideline development groups on testing and treating viral hepatitis.
Paul Kuehnert Robert Wood Johnson Foundation
Dr. Paul Kuehnert (Princeton NJ USA) is an associate vice president – program, for the Robert Wood Johnson Foundation where he provides leadership and management direction for the Foundation’s work related to leadership and transforming health and health care systems.
As an executive leader for the past 25 years, Paul has led both governmental and community-based organizations to help people lead healthier lives. He was a founder and later CEO of Community Response, Inc., one of the Chicago-area’s largest housing, nutrition and social service providers for people living with HIV/AIDS. Paul worked with the Maine health department and led the development of a regional public health system, and eventually became the department’s deputy director. Paul was also the county health officer and executive director for health in Kane County, Illinois, where he initiated and led a public-private partnership to reverse the epidemic of childhood obesity.
Paul is a pediatric nurse practitioner. He has a Doctor of Nursing Practice in executive leadership and a Master of Science in public health nursing from the University of Illinois at Chicago. He was named a Robert Wood Johnson Foundation Executive Nurse Fellow in 2004 and inducted into the American Academy of Nursing in 2015.
Wangsheng Li ZeShan Foundation
Mr. Wangsheng Li (Hong Kong SAR, China) is president of ZeShan Foundation (Hong Kong) and a Senior Fellow of the Synergos Institute (New York City). A private family foundation based in Hong Kong, ZeShan Foundation has made it a strategic focus for its Health Programs portfolio to foster strategic partnerships in the effective control and eventual elimination of viral hepatitis, with a particular emphasis on hepatitis B and an integrated approach to the prevention of mother to child transmission of HBV, HIV and syphilis.
This commitment is reflected in the Pledge of Action jointly announced by Ms. Laura Chen, ZeShan’s late executive chair and President Bill Clinton in 2008: “We commit to eliminating the transmission of hepatitis B and to reducing discrimination of those infected with the virus.”
Judith Monroe CDC Foundation
Dr. Judith Monroe (Atlanta, GA USA) is president and CEO of the CDC Foundation. The CDC Foundation mobilizes philanthropic and private-sector resources to support the critical health protection work of the U.S. Centers for Disease Control and Prevention (CDC). The Foundation manages over 300 CDC-led programs in the U.S. and in more than 130 countries. Under her leadership the Foundation responded to the Zika epidemic as an implementing partner in addition to mobilizing resources, supported the response and recovery from the 2017 hurricane season and serves as a strategic partner for global health security. Judy is a former CDC deputy director and director of the Office of State, Tribal, Local and Territorial Support. She also previously served as Indiana’s state health commissioner.
Prior to the CDC Foundation, Judy oversaw key activities and technical assistance at CDC supporting the nation’s health departments and the public health system. Throughout the 2014–15 Ebola epidemic she served as senior advisor for the domestic response. During her tenure as the state health commissioner for Indiana Judy served as president of the Association of State and Territorial Health Officials (ASTHO) through the H1N1 pandemic.
Judy received her M.D. from the University of Maryland and B.S. from Eastern Kentucky University, and an honorary doctorate from Purdue University in Health and Human Services.
Dr. Nicole M. Smith (Bainbridge Island, WA USA) was previously the Associate Director for Policy & Communication for the Division of Viral Hepatitis at the U.S. CDC. Nicole also has experience working as a policy director, epidemiologist, and program consultant on a variety of domestic and global health issues, such as vaccine-preventable diseases; seasonal, avian, and pandemic influenza preparedness and response; global health security; emergency preparedness and response; and, environmental health hazards. During her more than 25-year career, Nicole held a range of positions in the U.S. Public Health Service, including assignments with the World Health Organization in Kenya and Vietnam, and overseeing primary care projects in the U.S.-associated Pacific.
In addition to serving as a member of the EndHep2030 Oversight Committee, Nicole is a member of the Board of the American Liver Foundation.
Nicole received her BA from Brown University and her PhD, MPH, and MPP from the University of California at Berkeley; and is completing an MBA in Sustainable Systems from the Presidio Graduate School. Nicole also received applied epidemiology training through CDC’s Epidemic Intelligence Service program.
Mike van der Ven Pivotal Ventures
Mr. Mike van der Ven (Seattle, WA USA) joined Pivotal Ventures in June 2016. He serves as the primary owner and point of accountability for Pivotal finances, operational programs and projects. His two major areas of focus include organizational strategy and annual planning with a primary focus on efficiency and financial impact. Other focus areas include budget management, investments, key performance indicators (KPIs), IT and facilities management.
Mike joined Pivotal from Fred Hutch in Seattle where he was Director of Finance and Operations for the HIV Vaccine Trials Network. He oversaw all aspects of operations supporting a global network of 40 clinical trials sites and 2000 scientific collaborators working toward the development of a HIV Vaccine. Prior to his time at Fred Hutch, Mike worked in a dual role with the Clinton Health Access Initiative (CHAI) as Country Director for Cambodia and Director of Finance and Operations for the Southeast Asia region. In Cambodia, Mike managed programs that provided technical assistance to various departments within the Ministry of Health. Regionally, he provided operational management support to 5 other countries that was primarily focused on scaling up access to Adult and Pediatrics HIV care and treatment. Mike also worked for CHAI in Ethiopia as Deputy Country Director where he helped manage CHAI’s largest country office with programs that spanned the health sector.
Prior to joining CHAI, Mike spent four years working with the American Red Cross (ARC) as a Finance Manager for its Biomedical Services unit, and also as the Country Representative for the Maldives Tsunami Program managing operations and programs in Water & Sanitation and Psychosocial Support. He joined ARC in 2006 following a position at the World Bank in Washington DC, where he worked in a Leadership and Organizational Effectiveness group which focused on strengthening overall management capacity in the Bank across the globe. His background is in Financial Management, having also worked for PricewaterhouseCoopers in both the US and Australia.
Mike has an MBA from INSEAD in France, and an undergraduate degree in both Finance and Computer Applications from the University of Notre Dame in Indiana.
Stefan Wiktor University of Washington
Dr. Stefan Wiktor (Seattle, WA USA) is a University of Washington professor and public health physician with more than twenty-five years of experience in epidemiologic research and implementation of public health programs. He was the founding Team Lead of the WHO Global Hepatitis Programme in Geneva, Switzerland, which works with WHO Regional and country officials to promote the implementation of comprehensive viral hepatitis prevention and control programs.
While working for the U.S. CDC, Stefan conducted research studies of HIV-1 and HIV-2 epidemiology in West Africa and led the implementation of a large-scale HIV/AIDS prevention and treatment program in Tanzania. He is the author of more than 100 peer-reviewed scientific publications.
Stefan received his medical degree from Pennsylvania State University School of Medicine, public health degree from Johns Hopkins University and completed his internal medicine training at Georgetown University.
David Wilson World Bank
Dr. David Wilson (Washington DC, USA) is program director in the World Bank’s Health, Population and Nutrition global practice. He leads the World Bank’s Global Solutions Groups in support of Health Systems Strengthening for Universal Health Coverage.
Before joining the Bank in 2003, David worked as an academic, development practitioner and global health advisor in Africa for 20 years. David has published over 100 scientific papers and delivered over 1,000 scientific addresses. He has worked in high- and low-income contexts in over 50 countries on all continents. He has developed prevention programs that have been recognized as best practice by the World Bank, WHO and DFID, and that have been influential in international HIV prevention science.
In addition, David has served as technical consultant and adviser to many international agencies, including USAID, DFID, EU, AUSAID, SIDA, NORAD, UNAIDS, UNICEF and WHO.
Ray Yip Gates Foundation
Dr. Ray Yip (Beijing, China) has specialized in global health with more than twenty years of experience in public health program development and implementation in China through UNICEF, U.S. CDC, and the Bill & Melinda Gates Foundation.
Currently Ray serves as a strategic advisor to Mr. Bill Gates on China-related affairs and he supports the work of the Gates Foundation on partnership development for Chinese enterprise in investing in health and technology areas in Africa. Ray’s major areas of engagement include maternal and child health, nutrition, HIV/AIDS, and, vaccines and immunization.
Manal El-Sayed Ain Shams University
Dr. Manal El-Sayed (Cairo, Egypt) is Professor of Pediatrics at Ain Shams University. She is the clinical director of the national HCV Pediatric treatment program and the director of the clinical research unit and co-supervisor of the viral hepatitis treatment center at Ain Shams University. Manal has worked with pediatric hematology and oncology teams at Ain Shams University, National Cancer Institute, and 57357 Children’s Cancer Hospital since 1990.
Manal is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) charged with planning and implementing the nationwide program for prevention and management of viral hepatitis since 2006. She contributed to the establishment of a nationwide network of 55 specialized liver centers that provided interferon therapy to 350,000 HCV-infected patients. Since 2014 when the NCCVH introduced the new direct-acting antiviral agents for HCV, more than 1.9 million patients have been treated. Manal collaborated on the development of the national action plan for prevention and control of viral hepatitis published in October 2014 with representatives from WHO, the U.S. Centers for Disease Control and Prevention (U.S. CDC), Pasteur Institute, and national stakeholders. In addition to co-supervising the nationwide mass screening program for adults and children reaching so far more than 27 million people.
Manal is also an active board member and secretary general of the Egyptian Liver Care Society, a non-governmental organization that offers financial assistance to patients receiving treatment for hepatitis or liver transplants. She has authored and co-authored numerous journal articles on hepatitis and liver diseases, and participated in the development of WHO’s HBV, HCV and diagnostic guidelines. From 2011-2015, Manal was Vice Chair of WHO’s Technical Advisory Group for Prevention and Control of Viral Hepatitis in Egypt. She is also a board member of the European Study of Liver Disease International Liver Foundation since January 2018.
Annette Sohn TREAT Asia program
Dr. Annette Sohn (Bangkok, Thailand) joined amfAR’s staff as vice president and director of the TREAT Asia program in September 2008, and has since led amfAR’s office in Bangkok, Thailand. She oversees the integration of HIV-related research, education and training, and community and policy activities through TREAT Asia’s network of over 60 clinical centers in 14 countries in the Asia-Pacific.
Annette chairs the Executive Committee of the US National Institutes of Health’s IeDEA global cohort consortium (International Epidemiology Databases to Evaluate AIDS), and is a member of the National Advisory Child Health and Human Development Council of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. She sits on the World Health Organization’s Strategic and Technical Advisory Committee on HIV and Viral Hepatitis and Global Validation Advisory Committee on Elimination of Mother-to-Child Transmission of HIV and Syphilis. She is a co-Editor-in-Chief of the Journal of the International AIDS Society.
Saeed Sadiq Hamid Aga Khan University
Dr. Saeed Sadiq Hamid (Karachi, Pakistan) is Professor of Medicine and Director of the Clinical Trials Unit at the Aga Khan University, having served as the Ibne Sina Chairman, Department of Medicine over the past 10 years He is co-chair of the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP), member of the Technical Advisory Group on Viral Hepatitis to the government of Pakistan and Chair of the Hepatology Interest Group, World Gastroenterology Organization. He served as president of the Pakistan Society for the Study of Liver Diseases from 2011 to 2016.
Saeed is currently an associate editor for Hepatology International, the official journal of the Asian Pacific Association for the Study of the Liver (APASL). He is also a long serving member of the WHO Guidelines and Publications committee and chaired the WHO Guidelines Development Groups on HCV treatment guidelines that were released in April 2016 and revised in July 2018. Saeed was a member of the APASL Executive Council from 2006-2010 and continues to be a member of many APASL guideline development groups.
Saeed’s research interests include viral hepatitis and currently focus on Elimination of HCV from Pakistan. He has been the recipient of basic and clinical research grants, including clinical trials, and has numerous publications and book chapters to his credit. He is one of main authors on the recent Lancet Commission on Accelerating the Elimination of Viral. He graduated from King Edward Medical College, Lahore in 1981, and has been affiliated with Aga Khan University since 1990. He completed his postgraduate training in Medicine and Gastroenterology in the UK, and in Hepatology at the University of Texas Southwestern Medical School, Dallas.
Jinlin Hou Southern Medical University
Dr. Jinlin Hou (Guangzhou, China) is the Chairman and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University. He was the president of APASL from 2016-2017 and the immediate past president of Chinese Medical Association of Infectious Diseases from 2013-2016. Jinlin joined the University Department of Medicine of Nanfang Hospital in July 1984.
Jinlin trained in the Department of Medicine at St. Mary’s Hospital Medical School in London, UK in 1993-1994; and, was a senior visiting Fellow at the Institute of Hepatology, London, UK from 2000-2001. He has been invited to deliver talks at both national and international liver conferences given his expertise in viral hepatitis and other liver diseases. He has published more than 300 articles in both national and international journals, including Lancet Infectious Diseases, GUT, Hepatology, Journal of Hepatology, and Science.
Former OC Members
Lillian Lou The John C. Martin Foundation
Dr. Lillian Lou (California USA) has worked at The John C. Martin Foundation since its inception and formation in 2014. Prior to joining the Foundation, a private non-profit organization in the USA, Lillian has over 20 years of work experience in the pharmaceutical industry. She directed discovery biology research and clinical studies in several disease areas including hepatitis C and hepatitis B, respectively.
Previously at Gilead Sciences, as a member of the Access Program, she was responsible for leading the medical science activities in HIV/AIDS and viral hepatitis for developing countries. Lillian was trained as a research scientist and holds a PhD degree in biochemistry from University of California, Los Angeles. She was a National Institute of Health (NIH) post-doctoral research fellow at Stanford University in California. She was further trained in certification programs offered by University of California Santa Cruz and received certificates in clinical research and management, and regulatory affairs.
Conceived in collaboration with the World Health Organization, U.S. Centers for Disease Control and Prevention, and many other partners, EndHep2030 has been incubated by ZeShan Foundation since 2016 with operating support and seed funding.
Initial funding has also been provided by the CDC Foundation, John C Martin Foundation, and the Robert Wood Johnson Foundation.
EndHep2030 is a sponsored project of Rockefeller Philanthropy Advisors.
EndHep2030 was established under the leadership of the Hepatitis Elimination Partnership 2030 (HEP2030) Steering Committee.
WHO Global Hepatitis Programme
World Hepatitis Alliance
Department of Communicable Disease Prevention and Control,
WHO Regional Office for the Eastern Mediterranean
Vice President, Program
Robert Woods Johnson Foundation
Director and Partner
Social Sector Practice, McKinsey & Company
Wangsheng Li* Co-Chair
Ying-ru Jacqueline Lo*
HIV, Hepatitis & STD, WHO Western Pacific Regional Office
The John C. Martin Foundation
Viral Hepatitis Advisor
Médecins Sans Frontières
Director for China Program
Aaron Diamond AIDS Research Center at the Rockefeller University
Founder & Executive Director
Center for Disease Analysis
Deputy Director for Policy
Division of Viral Hepatitis, US Centers for Disease Control and Prevention
Mike van der Ven
Pivotal Ventures, Bill and Melinda Gates Foundation
Medical Officer (Viral Hepatitis)
WHO Western Pacific Regional Office
John Ward* Co-Chair
Division of Viral Hepatitis, US Centers for Disease Control and Prevention
Founding Director (retired)
WHO Global Hepatitis Programme
Term: Oct 2016 - Oct 2018
* Founding Member